Combination Therapy for Renal Cell Cancer: What Are Possible Options? | Zendy

Napoleon Santos | Zendy; Justin B. Wenger | Zendy; Pamela A. Havre | Zendy; Yanxia Liu | Zendy; Roi Dagan | Zendy; Iman Imanirad | Zendy; Alison Marguerite Ivey | Zendy; Robert A. Zlotecki | Zendy; Chester B. Algood | Zendy; Scott M. Gilbert | Zendy; Carmen J. Allegra | Zendy; Paul Okunieff | Zendy; Johannes Vieweg | Zendy; Nam H. Dang | Zendy; Hendrik Luesch | Zendy; Long H. Dang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combination Therapy for Renal Cell Cancer: What Are Possible Options?

Author(s) -

Napoleon Santos,

Justin B. Wenger,

Pamela A. Havre,

Yanxia Liu,

Roi Dagan,

Iman Imanirad,

Alison Marguerite Ivey,

Robert A. Zlotecki,

Chester B. Algood,

Scott M. Gilbert,

Carmen J. Allegra,

Paul Okunieff,

Johannes Vieweg,

Nam H. Dang,

Hendrik Luesch,

Long H. Dang

Publication year - 2011

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000333470

Subject(s) - sunitinib , pazopanib , sorafenib , medicine , renal cell carcinoma , bevacizumab , targeted therapy , combination therapy , tyrosine kinase inhibitor , oncology , cancer , kidney cancer , angiogenesis , vascular endothelial growth factor , drug , pharmacology , chemotherapy , vegf receptors , hepatocellular carcinoma

Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC). Two classes of antiangiogenic drugs, the anti-vascular endothelial growth factor antibody bevacizumab and the tyrosine kinase inhibitors sorafenib, sunitinib and pazopanib, have shown efficacy in patients with RCC and are approved by the US Food and Drug Administration for treatment of this cancer. In practice, the clinical benefit of antiangiogenic drugs in RCC has been heterogeneous, and in patients who do respond, benefits are modest and/or short-lived. To improve efficacy, combination targeted therapy has been attempted, but with either very limited additional efficacy or nontolerable toxicities. Recent advances in the molecular understanding of tumor angiogenesis and mechanism of resistance, along with the rapid development of targeted drug discovery, have made it possible to further explore novel combination therapy for RCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research